Related Experiment Video
Updated: May 1, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Combination treatment with synthetic gRNA/Cas12a and gRNA/Cas9 ribonucleoproteins disrupts HIV replication and
Puja Banik1,2, Ling Wang1,2, Madison Schank1,2
1Center of Excellence in Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
Abstract:
Eradication of HIV is challenging because of the integration of proviral DNA in reservoir cells. In this study, we evaluated the antiviral effects of synthetic gRNA/Cas12a and gRNA/Cas9 ribonucleoproteins (RNPs) in HIV-infected T cells and demonstrated their specificity and efficacy in disrupting HIV gene replication and expression. Notably, sequential or combinatorial treatments with gRNA4/Cas9 and/or gRNA5/Cas12a RNPs elicited the most effective antiviral effect, with significant reduction in integrated proviral DNA, HIV mRNA, early and late reverse transcripts, and p24 protein levels. DNA sequencing revealed a high rate of insertion and deletion or knockout frequencies at the HIV target genes. Gene alignment analysis showed a high level of conservation with both gRNA4/Cas9 and gRNA5/Cas12a target sequences across diverse regional HIV strains, indicating their potential to target different HIV strains across the world. This study indicates that synthetic gRNA4/Cas9 and gRNA5/Cas12a RNPs can be used for HIV gene disruption and viral eradication.
More Related Videos
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR
Retrovirus Life Cycles
Homologous Recombination
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
Inhibitors of Viral Protein Synthesis

